Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus oxaliplatin and capecitabine in early HER2-positive oesophagogastric cancer
2010-019602-16Phase 2Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Molecular response. Started Nov 2010; status: terminated.
02
Drugs
lapatinib
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2010-019602-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019602-16.